急性白血病患者化疗前后外周血淋巴细胞CR1的表达

The expression of CR1 in peripheral blood lymphocytes in patients with acute leukemia before and after chemotherapy

目的观察急性白血病患者化疗前、后外周血淋巴细胞(PBL)CR1表达的改变情况,探讨CR1测定在化疗疗效监测中的意义。方法采用免疫黏附法和ELISA法检测56例健康体检者和临床确诊的48例急性白血病患者的PBLCR1活性及含量,并对急性白血病患者化疗前、后的结果进行分析比较。结果 48例急性白血病患者PBLCR1活性为36.8±11.6;PBLCR1含量为0.73±0.18,均低于健康对照组(65.1±16.8)和(1.16±0.22),差异显著(P<0.05)。化疗后39例完全缓解者PBLCR1活性及含量水平回升(53.6±13.2)及(0.98±0.16),接近健康对照组(P>0.05),与化疗前比较差异也均有统计学意义(P<0.05),11例未缓解者PBLCR1活性和PBLCR1含量分别为(41.2±12.7)和(0.80±0.19),与化疗前比较略有升高,但无统计学意义(P>0.05)。结论急性白血病患者PBLCR1表达明显受到抑制,化疗缓解后PBLCR1活性及含量均有回升。检测外周血淋巴细胞CR1活性及含量可为临床急性白血病患者的免疫监测以及疗效评估、预后判断提供有价值的参考指标。

Objective To determine the expression of CR1 in peripheral blood lymphocytes（PBL） in acute leukemia patients be- fore and after chemotherapy,and to investigate the significance of monitoring CR1 in acute leukemia chemotherapy. Methods Im- mune adherence and ELISA were used to detect PBL CR1 activity and content, respectively,in 56 healthy individuals and 48 patients with definite diagnosis of acute leukemia. The expression of CR1 in acute leukemia patients before and after chemotherapy were also determined and analyzed. Results PBL CR1 activity and content in 48 patients with acute leukemia were 36.8 ± 11.6 and 0.73 ± 0.18, respectively, both lower than 65.1 ±16.8 and 1.16 ± 0.22 in healthy controls, respectively （P±0.05）. In 39 complete remis- sion patients after chemotherapy,PBL CR1 activity and content were 53.6±13.2 and 0.98 ± 0.16,respectively,close to those in healthy controls （P〈 0.05） and higher than those before chemotherapy （P〈0.05）. Furthermore, in 11 patients without remission, PBL CR1 activity and content were 41.2 ± 12.7 and 0.80 ± 0.19, respectively, slightly higher than those before chemotherapy, but had no statistically significance （P〈0.05）. Conclusion The expression of PBL CR1 in acute leukemia was obviously inhibited. However,in remission patients after chemotherapy, both PBL CR1 activity and content returned to normal level. Therefore, meas- urement of PBL CR1 activity and content might provide valuable information for immune status monitoring,treatment assessment and prognosis evaluation in acute leukemia patients.